The top surgical illumination company LumeN XT recently named its new Chairman of the Board. In a recent announcement, it named longtime executive and entrepreneur Marc Beer as the company’s new Chairman of the Board. Beer will take over one of the top leadership positions in the company. For many years, Marc Beer established himself as one of the most successful entrepreneurs and executives in the pharmaceutical and biotechnology industries. He will look to help LumeN XT continue making progress towards developing surgical illumination technology. Learn more: https://ideamensch.com/marc-beer/
Shortly after being named as the new Chairman of the Board of the company, Marc Beer had a few remarks about the company and its team of professionals. Marc said that he is very happy to be working with some of the most competent and innovative engineers in the biotechnology industry. He is also thrilled to be working with a group of dedicated surgeons who are very experienced with using surgical illumination technology. Beer also mentioned that the surgical illumination procedures are among the least invasive available and will likely advance the quality of healthcare in the near future.
Since the introduction of surgical illumination procedures, the healthcare industry has been able to make important progress towards providing better care for patients. One of the ways in which it has helped the healthcare industry improve is by making it easier for professionals to complete their tasks. For surgeons, they are now able to have enhanced vision as well as be more precise when performing surgical procedures. They are also able to take advantage of more flexibility during operations as well. LumeN XT has been able to use surgical illumination technology to make valuable contributions to the healthcare industry. These contributions include more precise surgeries, lower costs and improved safety for surgeons and patients.
LumeNXT co founder Paul Rhyne expressed his viewpoint on the recent appointment of Marc Beer as the new Chairman of the Board. In his statement, Rhyne said that Marc has proven himself as both an executive and as an entrepreneur. Over the course of his career, Marc has been able to provide valuable guidance to healthcare companies in their startup and expansion process. Under Beer’s leadership, these companies have been able to raise revenues, increase profits, introduce better solutions and also complete expansion. Therefore, Marc will likely become a valuable contributor to LumeN XT in the near future.
Marc Beer has recently been associated with a medical device technology company known as Renovia. This company helped develop technology to treat pelvic floor disorders. He was also a founder and chairman at Minerva Neurosciences which developed treatments for a number of conditions associated with the central nervous system. Over the years, Marc has held top managerial positions at other healthcare and biotechnology companies. As a top executive, he helped these companies improve their products and services as well as assist them with their expansion to multiple markets worldwide.
Renovia Inc. can now proceed with now projects after CEO Marc Beer helped the company to raise $42M. The money will be used to promote products meant for the treatment of pelvic floor disorders, and there is expected to be a significant boost in the new research. The CEO said that a large sum of the money was raised through a series B round while the remainder was collected through venture debt. This is good news for the company which has been exploring various ways to fund its operations and to venture into new markets.
Diagnostic and therapeutic products
Based in Boston, Renovia Inc. is trying to develop the latest diagnostic and therapeutic products that will help over 250,000 women suffering from pelvic floor disorder. The necessity for these programs stems from the fact that these women have been experiencing a lot of difficulties in managing this condition. In addition to that, the doctors who have been trying to help them have had little help from the available products and therefore, it was important to develop something that will cater to these limitations. Their products have been designed after a long period of research.
The Longwood Fund contribution
To raise the money, Renovia had to rely heavily on the Longwood Fund. This is a healthcare company that had earlier invested in Renovia, and therefore, it was instrumental in raising the money. It is this company that joined the B round, and it is through this round that $32 out of the $42 was collected. With such a contribution, there is no doubt that the company has cemented its investment and so, it is going to play a significant role in determining the future of Renovia. There were other players involved in the collection of the funds. Learn more: https://www.bizjournals.com/boston/potmsearch/detail/submission/6457372/Marc_Beer
A new version of Leva
While announcing the news, CEO Marc Beer said that one of the solutions that the company was going to develop using the money was a new version of Leva. The Leva has been instrumental in the diagnosis and treatment of various conditions, but the company feels that an upgrade would be more ideal. Indeed, their desire is to come up with better solutions that solve new challenges and so, it informs their decisions.
About Marc Beer
Marc Beer is the chairman, Chief Executive Officer, and co-founder of Renovia, a women startup company that develops diagnostic solutions for the treatment of various conditions. He has over 25 years of experience in the industry and has worked with some of the leading companies. In addition to that, Marc has served as a member of the boards of various organizations. It is his vast experience in management that has helped him to get Renovia Inc. to a perfect start by collecting funds on time and ensuring that projects are not interrupted.
Accomplished businessman Marc Beer has recently raised over forty million dollars for his women’s health startup. When beginning this endeavor, Beer pledged a great deal of his experience and wealth to this women’s health startup. He co-founded the startup, called Renovia Inc., to utilize his skill and background in development and commercial experience in the field of pelvic floor disorders of women.
Renovia Inc. was founded in 2016 with the aim of improving diagnosis and treatment for the millions of women that have pelvic floor disorders, hoping to advance their quality of life that has been specific to their condition in the past. Women with pelvic floor disorders, such as urinary tract incontinence, can be grateful to Renovia Inc. for its development of a product pipeline that could potentially utilize an app to visualize and diagnose pelvic movement. Renovia Inc. already boasts an FDA-cleared device called Leva, which not only strengthens pelvic floor muscles, but can also treat a woman’s stress and urinary incontinence.
The recent raising of funds for the company comes from 10 million dollars in venture debt and 32 million in Series B investment. The startup funds will be used to proceed in the research and development of several new products, which will also be aimed toward women that suffer from pelvic floor issues. The products will span from diagnostic to therapeutic means of use, and will all be geared toward solving pelvic floor issues, such as urinary incontinence, that effect over 250 million women throughout the world.
The Series B round welcomed investors such as Ascension Ventures of Missouri, Perceptive Advisors of New York, and, most recently, a healthcare-based investing firm called The Longwood Fund.
Renovia’s CEO Marc Beer states his gratitude toward the healthcare companies investments, and welcomes them on board for the upcoming testing and development. He mentions that he feels his vision of improving the lives of those women effected by pelvic disorders is shared by investors, and is looking forward to innovating the technologies and digital health platforms that will grow the data and knowledge of pelvic floor disorders. Research and gathering of information will not only provide therapeutic treatment to these women, but also has the potential to lower healthcare costs in the long run. Learn more: https://gazetteday.com/2018/10/marc-beer-funding-renovia/
The new products to be released will include four products that are involved in the therapy and diagnosis of pelvic floor disorders, one of which is a new model of the Leva device that is currently on the market from Renovia.